z-logo
open-access-imgOpen Access
Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease
Author(s) -
Huh Terry,
LaroucheLebel Éva,
Loughran Kerry A.,
Oyama Mark A.
Publication year - 2020
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.15948
Subject(s) - telmisartan , cats , angiotensin ii receptor type 1 , medicine , renin–angiotensin system , angiotensin ii , endocrinology , aldosterone , incubation , angiotensin receptor , angiotensin converting enzyme , plasma renin activity , receptor , chemistry , blood pressure , biochemistry
Background Little is known about the effect of renin angiotensin aldosterone system‐inhibiting (RAASi) drugs on alternative angiotensin peptides (APs) such as angiotensin 1‐7 (Ang1‐7), which are mediated by angiotensin‐converting enzyme 2 (ACE2). Hypothesis/Objectives Angiotensin receptor blockers (ARBs) would alter balance of APs and differences would be magnified in vitro by incubation of plasma samples with recombinant human ACE2 (rhACE2). Animals Six cats with cardiomyopathy (CM), 8 healthy cats. Methods Prospective open label trial. Plasma equilibrium concentrations of APs were measured in healthy cats as well as in CM cats that first received no RAASi drugs (CM noRAASi ) and then after 14 days of PO telmisartan (CM ARB ). Plasma APs also were measured after in vitro incubation with rhACE2. Results No significant differences were found between healthy and CM noRAASi groups. Concentrations of several APs, including angiotensin I (AT1) and angiotensin II (AT2) were significantly different between CM noRAASi and CM ARB groups. Incubation with rhACE2 decreased AT1 and AT2 in both groups. The geometric mean concentration of Ang1‐7 was significantly higher in CM ARB (4.9 pg/mL; 95% confidence interval [CI], 3.7‐6.4 pg/mL) vs CM noRAASi (3.2 pg/mL; 95% CI, 2.2‐4.7 pg/mL; P = .01) and in CM ARB  + ACE2 (5.0 pg/mL; 95% CI, 3.9‐6.4 pg/mL) vs CM noRAASi  + ACE2 (3.0 pg/mL; 95% CI, 1.7‐5.5 pg/mL; P = .01). The most favorable theoretical AP profile that maximized Ang1‐7 and other alternative APs was CM ARB  + ACE2. Conclusions and Clinical Importance Balance between traditional and alternative APs can be favorably shifted using ARBs and in vitro incubation with rhACE2. These data shed light on new AP‐targeting strategies in cats with CM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here